Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Researchs GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and published earlier this year in JAMA Internal Medicine
The GLP-1 and GIP components enhance insulin secretion and sensitivity, while the glucagon component, somewhat paradoxically, does not worsen blood sugar control because its glucose-raising effects are offset by the dominant insulin-enhancing effects of the other two pathways
Others experience gradual benefits over several weeks of consistent use
Current prescriptions for GLP-1 RAs include boxed warnings for increased risk of development of MTC (11)
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
